Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia
In plain words A study of D-ribose in people 18 to 65, run by Haydarpasa Numune Training and Research Hospital. It plans to enroll about 200 people at 5 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Fibromyalgia Syndrome; Fibromyalgia.
- Adults aged 18 to 65 years
- Diagnosis of fibromyalgia syndrome according to the 2016 ACR criteria
- Followed in a physical medicine and rehabilitation outpatient clinic for at least 1 year
- Receiving pregabalin and/or duloxetine treatment for at least 3 months
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
2-Aticyto Complex and D-ribose Oral Supplement; Placebo syrup
Registered summary
This multicenter, randomized, double-blind, placebo-controlled study will evaluate whether an oral supplement containing 2-Aticyto Complex and D-ribose (FibroThol), added to ongoing standard medical treatment, improves pain, symptoms, and clinical course in adults with fibromyalgia syndrome. Eligible participants are adults aged 18 to 65 years who have had fibromyalgia for at least 1 year and have been receiving pregabalin and/or duloxetine for at least 3 months. The full summary is on the listing.
Where, as registered
No US site; Turkey (Türkiye) (5).